Chisenga Caroline Cleopatra, Phiri Bernard, Ng'ombe Harriet, Muchimba Mutinta, Musukuma-Chifulo Kalo, Silwamba Suwilanji, Laban Natasha Makabilo, Luchen Chaluma, Liswaniso Fraser, Chibesa Kennedy, Mubanga Cynthia, Mwape Kapambwe, Simuyandi Michelo, Cunningham Adam F, Sack David, Bosomprah Samuel
Enteric Disease and Vaccine Research Unit, Centre for Infectious Disease Research in Zambia, Lusaka P.O. Box 34681, Zambia.
Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Vaccines (Basel). 2024 Apr 8;12(4):390. doi: 10.3390/vaccines12040390.
Despite the successful introduction of oral cholera vaccines, Zambia continues to experience multiple, sporadic, and protracted cholera outbreaks in various parts of the country. While vaccines have been useful in staying the cholera outbreaks, the ideal window for re-vaccinating individuals resident in cholera hotspot areas remains unclear. Using a prospective cohort study design, 225 individuals were enrolled and re-vaccinated with two doses of Shanchol™, regardless of previous vaccination, and followed-up for 90 days. Bloods were collected at baseline before re-vaccination, at day 14 prior to second dosing, and subsequently on days 28, 60, and 90. Vibriocidal assay was performed on samples collected at all five time points. Our results showed that anti-LPS and vibriocidal antibody titers increased at day 14 after re-vaccination and decreased gradually at 28, 60, and 90 days across all the groups. Seroconversion rates were generally comparable in all treatment arms. We therefore conclude that vibriocidal antibody titers generated in response to re-vaccination still wane quickly, irrespective of previous vaccination status. However, despite the observed decline, the levels of vibriocidal antibodies remained elevated over baseline values across all groups, an important aspect for Zambia where there is no empirical evidence as to the ideal time for re-vaccination.
尽管口服霍乱疫苗已成功引入,但赞比亚仍在该国各地不断经历多次、零星且持久的霍乱疫情。虽然疫苗在控制霍乱疫情方面发挥了作用,但霍乱热点地区居民再次接种疫苗的理想时机仍不明确。采用前瞻性队列研究设计,招募了225名个体,无论其之前是否接种过疫苗,均再次接种两剂Shanchol™,并随访90天。在再次接种前的基线、第二次接种前的第14天以及随后的第28天、60天和90天采集血液。对在所有五个时间点采集的样本进行杀菌试验。我们的结果显示,再次接种后第14天,抗脂多糖和杀菌抗体滴度升高,在所有组中,第28天、60天和90天时逐渐下降。所有治疗组的血清转化率总体相当。因此,我们得出结论,无论之前的疫苗接种状况如何,再次接种后产生的杀菌抗体滴度仍会迅速下降。然而,尽管观察到抗体滴度下降,但所有组的杀菌抗体水平仍高于基线值,这对于赞比亚来说是一个重要方面,因为目前尚无关于再次接种理想时间的实证证据。